Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.
British Journal of Haematology (impact factor: 4.94). 12/2007; 139(3):511-2. DOI:10.1111/j.1365-2141.2007.06806.x pp.511-2
[show abstract] [hide abstract]
ABSTRACT: Polycythemia vera (PV) was first described nearly 120 years ago. In the subsequent century, the clinical syndrome of PV, its natural history, its treatment, and many critical pathogenetic features of the disease were characterized. The discovery of the Janus-associated kinase - 2 mutation JAK2 V617F and the characterization of its role in myeloproliferative neoplasms have substantially changed the diagnostic paradigm for PV, and have potential to lead to new therapy and new pathogenetic insights.The Korean journal of hematology 06/2010; 45(2):90-4.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.